Abstract:The mechanisms of neuro-genetic disorders have been mostly investigated in the brain, however, for some pathologies, transcriptomic analysis in multiple tissues represent an opportunity and a challenge to understand the consequences of the genetic mutation. This is the case for Rett Syndrome (RTT): a neurodevelopmental disorder predominantly affecting females that is characterised by a loss of purposeful movements and language accompanied by gait abnormalities and hand stereotypies. Although the genetic aetiology is largely associated to Methyl CpG binding protein 2 (MECP2) mutations, linking the pathophysiology of RTT and its clinical symptoms to direct molecular mechanisms has been difficult.One approach used to study the consequences of MECP2 dysfunction in patients, is to perform transcriptomic analysis in tissues derived from RTT patients or Induced Pluripotent Stem cells. The growing affordability and efficiency of this approach has led to a far greater understanding of the complexities of RTT syndrome but is also raised questions about previously held convictions such as the regulatory role of MECP2, the effects of different molecular mechanisms in different tissues and role of X Chromosome Inactivation in RTT.In this review we consider the results of a number of different transcriptomic analyses in different patients-derived preparations to unveil specific trends in differential gene expression across the studies. Although the analyses present limitations- such as the limited sample size- overlaps exist across these studies, and they report dysregulations in three main categories: dendritic connectivity and synapse maturation, mitochondrial dysfunction, and glial cell activity.These observations have a direct application to the disorder and give insights on the altered mechanisms in RTT, with implications on potential diagnostic criteria and treatments.

The molecular pathology of rett syndrome

Downregulation of CNPase in a MeCP2 Deficient Mouse Model of Rett Syndrome.

Selective Preservation of Cholinergic Mecp2 Rescues Specific Rett-Syndrome-Like Phenotypes in Mecp2(Stop) Mice

Regulation Mechanism and Research Progress of MeCP2 in Rett Syndrome

Research Progress of Rett Syndrome Causing Gene MECP2-The Structure, Function and Modulation of MECP2

Rett Syndrome Linked to Defects in Forming the MeCP2/Rbfox/LASR Complex in Mouse Models

Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2

Rett Syndrome-Causing Mutations Compromise MeCP2-mediated Liquid–liquid Phase Separation of Chromatin

Rett Syndrome and the Role of MECP2: Signaling to Clinical Trials

MECP2 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

Global Impairment of Immediate-Early Genes Expression in Rett Syndrome Models and Patients Linked to Myelination Defects

X Chromosome Inactivation in Rett Syndrome and Its Correlations with MECP2 Mutations and Phenotype.

Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes

MECP2 Mutation Spectrum and Its Clinical Characteristics in a Chinese Cohort

MeCP2 links heterochromatin condensates and neurodevelopmental disease

Genetic and Protein Network Underlying the Convergence of Rett-Syndrome-like (RTT-L) Phenotype in Neurodevelopmental Disorders

Genome-Wide Analysis Reveals Methyl-Cpg-Binding Protein 2-Dependent Regulation Of Micrornas In A Mouse Model Of Rett Syndrome

Genes Related to Mitochondrial Functions, Protein Degradation, and Chromatin Folding Are Differentially Expressed in Lymphomonocytes of Rett Syndrome Patients

Transcriptome level analysis in Rett syndrome using human samples from different tissues

MECP2 and CDKL5 Gene Mutation Analysis in Chinese Patients with Rett Syndrome

A novel pathogenic mutation of MeCP2 impairs chromatin association independent of protein levels